查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1471193

单株抗体治疗市场：按来源、最终用户、应用分类 - 2024-2030 年全球预测

Monoclonal Antibody Therapeutics Market by Source (Chimeric, Human, Humanized), End User (Hospitals, Private Clinics, Research Institute), Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年单株抗体治疗市场规模为1,533.5亿美元，预估2024年将达1,698.7亿美元，2030年将达3,253.7亿美元，复合年增长率为11.34%。

单株抗体 (mAb) 疗法涉及使用实验室设计的抗体来模拟免疫系统靶向和消灭病毒和细菌等有害病原体的能力。单株抗体旨在针对和中和特定病原体，对治疗多种疾病非常有效，包括癌症、自体免疫疾病、感染疾病和循环系统疾病。全球范围内慢性疾病（例如癌症和自体免疫疾病）的发生率不断增加，由于其治疗的特异性和有效性，显着增加了对单株抗体疗法的需求。众多针对生物製药研究和开发的政府计划和资助机会正在对单株抗体治疗市场产生积极影响。然而，从小规模实验室生产转向大规模商业生产面临挑战，例如维持产品品质和一致性。单株抗体可以引发患者的免疫反应，而其他效能限制则会影响疗效和安全性。主要企业正在透过将单株抗体与强大的细胞毒性药物结合来增强单株抗体的治疗效果，以改善癌症和其他严重的治疗。生物加工方面的创新，例如连续製造和一次性技术，可以解决当前的生产和可扩展性挑战，降低成本并提高可及性。此外，向个人化医疗的转变以及将抗体药物复合体纳入各种疾病的治疗中，为单株抗体疗法创造了新的可能性。

主要市场统计
基准年[2023] 1533.5亿美元
预测年份 [2024] 1698.7亿美元
预测年份 [2030] 3253.7亿美元
复合年增长率（%） 11.34%

来源 人类单株抗体由于其低免疫抗原性而变得普及

嵌合体单株抗体是人工抗体，其中大部分抗体分子源自人类，只有一小部分源自非人类物种（通常是小鼠）。与小鼠源性单株抗体相比，这种组合降低了免疫抗原性并维持了所需的抗原特异性。人类单株抗体由人类基因和蛋白质製成。这种方法显着降低了免疫抗原性反应的可能性，并使这些抗体与人体免疫系统更相容。人类单株抗体是使用噬菌体展示和基因转殖小鼠等技术生产的，这些技术可产生人类抗体，在治疗应用中提供高特异性和安全性。人源化单株抗体是将非人类抗体的互补决定区（特异性抗原结合部分）移植到人类抗体的骨架上而产生的。此方法可显着降低免疫抗原性，同时保持抗体标靶的特异性。人源化抗体在保留非人类抗体所需的活性和最大限度地减少对它们的潜在免疫反应之间取得了平衡。

最终使用者：在医院中越来越多地采用，准确的诊断监测和管理通常涉及静脉注射

单株抗体疗法在医院用于管理和治疗癌症、自体免疫疾病和感染疾病等慢性疾病。这种用途源于特异性针对患病细胞和病原体而不影响周围健康组织的能力，从而减少副作用并加速患者康復。在私人诊所，这些治疗药物主要用于治疗需要个人化治疗通讯协定的疾病患者，例如类风湿性关节炎、干癣和其他自体免疫疾病。单株抗体的高精度可以实现量身定制的治疗，提高治疗效果并改善患者的治疗结果。研究机构正利用单株抗体疗法作为推进医学科学的重要工具。研究机构对于开发新治疗方法和阐明疾病机制至关重要。这些研究机构专注于创新和改进单株抗体技术，为各个医学领域的下一代治疗方法铺路。

区域洞察

以美国和加拿大为中心的美洲地区拥有高度发展和发展的研发环境，拥有先进的研究设施、庞大的医疗成本以及保护创新的强大专利环境。美国消费者的需求很大程度上是由对癌症、自体免疫疾病和其他慢性病的有效、有针对性的治疗的需求所驱动的。美国食品药物管理局（FDA）积极核准单株抗体疗法，进一步推动市场成长。最近的投资主要集中在癌症研究上，生技公司和政府为创新治疗方法提供资金。欧盟（EU）国家是全球单株抗体治疗市场的主要贡献者。优质的医疗保健系统、广泛的研究网络和有利的政府政策支持该地区的市场成长。欧盟消费者需求的特征是越来越偏好个人化医疗和创新治疗选择。欧洲药品管理局 (EMA) 促进新治疗方法的核准，最近的重点是癌症和免疫学。关于单株抗体的性能、安全性、功效和生产的严格规定为治疗学的进步提供了标准化框架。由于政府在生物技术和医疗保健方面的大量投资，亚太地区的单株抗体治疗市场正在迅速扩大。中国政府对生物医学和医疗改革的支持正在为研究和引进新治疗方法创造机会。日本是亚洲领先的医疗保健市场之一，消费者对创新单株抗体疗法（尤其是与年龄相关的疾病）表现出强劲的需求。印度的景观正在崛起，医疗保健意识的提高和医疗服务的改善推动了成长。为了有效满足消费者的需求，本地生产和降低处理成本越来越受到重视。

FPNV定位矩阵

FPNV 定位矩阵对于评估单株抗体治疗市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对单株抗体治疗市场供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告对以下几个方面提供了宝贵的见解：

1. 市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2. 市场开拓：我们深入研究利润丰厚的新兴市场，并分析其在成熟细分市场的渗透率。

3. 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4. 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况和製造能力进行全面评估。

5. 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1.单株抗体治疗市场的市场规模与预测是多少？

2.单株抗体治疗市场预测期间需要考虑投资的产品、细分市场、应用和领域有哪些？

3.单株抗体治疗市场的技术趋势和法规结构是什么？

4.单株抗体治疗市场主要厂商的市场占有率是多少？

5.进入单株抗体治疗市场的合适型态和策略性手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地慢性病和遗传疾病的发生率正在增加，需要紧急的治疗策略。
      • 单株抗体的监管核准
      • 政府努力促进患者获得关键的单株抗体疗法
    • 抑制因素
      • 与储存和处理相关的生产问题和困难
    • 机会
      • 不断进步和研发努力，以提高单株抗体疗法的功效和安全性
      • 个人化医疗的趋势和引入抗体药物复合体进行治疗
    • 任务
      • 表现的限制和治疗效果的变化
  • 市场区隔分析
    • 资料来源：由于免疫抗原性低，人类单株抗体越来越普及
    • 最终使用者：医院越来越多地采用该技术增加了对静脉输液进行准确诊断监测和管理的需求。
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章单株抗体治疗市场：依来源分类

  • 嵌合体
  • 人类
  • 人性化

第七章 单株抗体治疗市场：依最终使用者分类

  • 医院
  • 私人诊所
  • 调查机构

第八章单株抗体治疗市场：依应用分类

  • 自体免疫疾病
  • 癌症
  • 血液疾病
  • 感染疾病
  • 眼科疾病

第九章 北美和南美单株抗体治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区单株抗体治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的单株抗体治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 罗氏製药印度公司以双通路抑制剂 Vavismo 进军眼科领域
    • 艾伯维 (AbbVie) 和 OSE 免疫疗法合作治疗慢性发炎
    • 诺华收购 Calypso Biotech 扩大自体免疫产品组合
  • 战略分析和建议

第13章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-4316E4E89474

[187 Pages Report] The Monoclonal Antibody Therapeutics Market size was estimated at USD 153.35 billion in 2023 and expected to reach USD 169.87 billion in 2024, at a CAGR 11.34% to reach USD 325.37 billion by 2030.

Monoclonal antibody (mAb) therapeutics involves the use of antibodies engineered in the laboratory to mimic the immune system's ability to target and destroy harmful pathogens such as viruses and bacteria. Monoclonal antibodies are designed to target and neutralize specific pathogens, making them highly effective in the treatment of a variety of diseases, including cancer, autoimmune diseases, infectious diseases, and cardiovascular disorders. The growing incidence of chronic diseases worldwide, such as cancer and autoimmune disorders, significantly drives the need for monoclonal antibody therapeutics due to their specificity and efficacy in treatment. Numerous government programs and funding opportunities for research and development in biopharmaceuticals have positively impacted the monoclonal antibody therapeutics market. However, transitioning from small-scale laboratory production to large-scale commercial production presents challenges, including maintaining product quality and consistency. The potential of monoclonal antibodies to trigger immune responses in patients and other performance limitations affects efficacy and safety profiles. Key players are enhancing the therapeutic efficacy of monoclonal antibodies by conjugating them with potent cytotoxic to improve the treatment of cancers and other severe diseases. Innovations in bioprocessing, such as continuous manufacturing and single-use technologies, can address current production and scalability challenges, reducing costs and improving accessibility. Moreover, the shift towards personalized medicine and the incorporation of antibody-drug conjugates for the treatment of various diseases has further created new avenues of opportunities for monoclonal antibody therapeutics.

KEY MARKET STATISTICS
Base Year [2023] USD 153.35 billion
Estimated Year [2024] USD 169.87 billion
Forecast Year [2030] USD 325.37 billion
CAGR (%) 11.34%

Source: Rising prevalence of human monoclonal antibodies due to their lower immunogenicity

Chimeric monoclonal antibodies are engineered antibodies where the majority of the antibody molecule is derived from human sources, with a minor portion being sourced from non-human species, typically mice. This combination reduces immunogenicity compared to fully murine monoclonal antibodies while retaining the desired antigen specificity. Human monoclonal antibodies are sourced from human genes and proteins. This approach significantly decreases the potential for immunogenic reactions, making these antibodies more compatible with human immune systems. They are produced using techniques such as phage display or transgenic mice engineered to produce human antibodies, offering high specificity and safety in therapeutic applications. Humanized monoclonal antibodies are created by grafting the non-human antibody's complementarity-determining regions (the specific parts that bind to the antigen) onto a human antibody framework. This method maintains the antibody's specificity towards its target while significantly reducing its immunogenicity. Humanized antibodies balance retaining the desired activity of non-human antibodies and minimizing potential immune responses against them.

End User: Increasing adoption in hospitals necessity for precise diagnostic oversight and administration typically involving intravenous infusion

In hospitals, monoclonal antibody therapeutics are used to manage and treat chronic illnesses such as cancer, autoimmune diseases, and infectious diseases. This utilization stems from their ability to specifically target diseased cells or pathogens without affecting surrounding healthy tissues, thus limiting side effects and promoting rapid patient recovery. In private clinics, these therapeutics find application primarily in treating patients with conditions that require personalized care protocols, including rheumatoid arthritis, psoriasis, and other autoimmune disorders. The precision of monoclonal antibodies allows for tailored treatments, enhancing the effectiveness of therapy and improving patient outcomes. Research institutes leverage monoclonal antibody therapeutics as pivotal tools in advancing medical science. They are crucial for the development of new treatment modalities and the understanding of disease mechanisms. These institutes focus on innovating and improving monoclonal antibody technologies, thus paving the way for the next generation of therapies in various fields of medicine.

Regional Insights

The Americas region, particularly the U.S. and Canada, presents a highly evolved and developed landscape for monoclonal antibody therapeutics, attributed to pioneering research facilities, substantial healthcare spending, and a robust patent environment that protects innovations. Consumer needs in the U.S. are largely driven by a requirement for effective and targeted therapies for cancer, autoimmune diseases, and other chronic conditions. The U.S. Food and Drug Administration (FDA) has been proactive in approving monoclonal antibody treatments, further stimulating market growth. Recent investments mainly focus on cancer research, with biotech companies and the government funding innovative treatments. The European Union (EU) countries contribute significantly to the global monoclonal antibody therapeutics market. High-quality healthcare systems, extensive research networks, and favorable government policies support market growth in the region. Consumer needs in the EU are characterized by an increasing preference for personalized medicine and innovative treatment options. The European Medicines Agency (EMA) facilitates the approval of new therapies, with recent focus areas including oncology and immunology. Stringent regulations for the performance, safety, efficacy, and production of monoclonal antibodies provide a standardized framework for the progress of therapeutics. APAC's monoclonal antibody therapeutics market is expanding rapidly, thanks to substantial government investments in biotechnology and healthcare. The Chinese government's support for biomedical sciences and healthcare reforms has created opportunities for research and the adoption of novel therapies. As one of the leading healthcare markets in Asia, Japan demonstrates strong consumer demand for innovative monoclonal antibody therapies, particularly for aging-related diseases. India's monoclonal antibody therapeutics landscape is emerging, with growth driven by increasing healthcare awareness and improving access to healthcare. Local production and reduced treatment costs are areas of focus to meet consumer needs effectively.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Monoclonal Antibody Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Monoclonal Antibody Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Monoclonal Antibody Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Bayer AG, Biogen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Envigo, F. Hoffmann-La Roche Ltd, GenScript, GlaxoSmithKline Plc, Johnson & Johnson, Merck Sharp & Dohme Corp.,, Novartis International AG, Pfizer Inc, and Sanofi S.A.

Market Segmentation & Coverage

This research report categorizes the Monoclonal Antibody Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Source
    • Chimeric
    • Human
    • Humanized
  • End User
    • Hospitals
    • Private Clinics
    • Research Institute
  • Application
    • Autoimmune Diseases
    • Cancer
    • Hematological Diseases
    • Infectious Diseases
    • Ophthalmological Diseases
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Monoclonal Antibody Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Monoclonal Antibody Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Monoclonal Antibody Therapeutics Market?

4. What is the market share of the leading vendors in the Monoclonal Antibody Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Monoclonal Antibody Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidences of chronic and genetic diseases across the world and the need for urgent treatment strategies
      • 5.1.1.2. Favorable regulatory approvals for monoclonal antibodies
      • 5.1.1.3. Government initiatives to promote access to critical monoclonal antibody therapies for patients
    • 5.1.2. Restraints
      • 5.1.2.1. Production issues and difficulties associated with storage and handling
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements and R&D activities to improve the efficacy and safety of monoclonal antibody therapeutics
      • 5.1.3.2. Inclinations towards personalized medicine and incorporation of antibody-drug conjugates for treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Performance limitations and variability in treatment effect
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Source: Rising prevalence of human monoclonal antibodies due to their lower immunogenicity
    • 5.2.2. End User: Increasing adoption in hospitals necessity for precise diagnostic oversight and administration typically involving intravenous infusion
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Monoclonal Antibody Therapeutics Market, by Source

  • 6.1. Introduction
  • 6.2. Chimeric
  • 6.3. Human
  • 6.4. Humanized

7. Monoclonal Antibody Therapeutics Market, by End User

  • 7.1. Introduction
  • 7.2. Hospitals
  • 7.3. Private Clinics
  • 7.4. Research Institute

8. Monoclonal Antibody Therapeutics Market, by Application

  • 8.1. Introduction
  • 8.2. Autoimmune Diseases
  • 8.3. Cancer
  • 8.4. Hematological Diseases
  • 8.5. Infectious Diseases
  • 8.6. Ophthalmological Diseases

9. Americas Monoclonal Antibody Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Monoclonal Antibody Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Monoclonal Antibody Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Roche Pharma India Enters into Ophthalmology with Dual-Pathway-Inhibitor Vabysmo
    • 12.3.2. Partnership between AbbVie and OSE Immunotherapeutics for Chronic Inflammation Treatment
    • 12.3.3. Novartis Expands Autoimmune Portfolio with Acquisition of Calypso Biotech
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. MONOCLONAL ANTIBODY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. MONOCLONAL ANTIBODY THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. MONOCLONAL ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CHIMERIC, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMAN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HUMANIZED, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY PRIVATE CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY HEMATOLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGICAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 36. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 37. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 38. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 39. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 40. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 43. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 44. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 45. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 46. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 47. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 48. ARGENTINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 49. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 50. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 51. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 52. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 53. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 54. BRAZIL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 55. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 56. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 57. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 58. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 59. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 60. CANADA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 61. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 62. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 63. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 64. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 65. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 66. MEXICO MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 67. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 68. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 69. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 70. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 71. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 74. UNITED STATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 84. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 86. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. AUSTRALIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 90. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 91. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 92. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 93. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 94. CHINA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 95. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 96. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 97. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 98. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 99. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. INDIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 102. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 103. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 104. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 105. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 106. INDONESIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 107. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 108. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 109. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 110. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 111. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 112. JAPAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 113. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 114. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 115. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 116. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 117. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 118. MALAYSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 120. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 122. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. PHILIPPINES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 126. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 127. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 128. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 129. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 130. SINGAPORE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 132. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 134. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 136. SOUTH KOREA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 137. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 138. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 139. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 140. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 141. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 142. TAIWAN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 143. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 144. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 145. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 146. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 147. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. THAILAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. VIETNAM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 150. VIETNAM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 151. VIETNAM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 152. VIETNAM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 153. VIETNAM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 154. VIETNAM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 163. DENMARK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 164. DENMARK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 165. DENMARK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 166. DENMARK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 167. DENMARK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 168. DENMARK MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 169. EGYPT MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 170. EGYPT MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 171. EGYPT MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 172. EGYPT MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 173. EGYPT MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. EGYPT MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. FINLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 176. FINLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 177. FINLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 178. FINLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 179. FINLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. FINLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 182. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 183. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 184. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 185. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 186. FRANCE MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 187. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 188. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 189. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 190. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 191. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 192. GERMANY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 193. ISRAEL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 194. ISRAEL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 195. ISRAEL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 196. ISRAEL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 197. ISRAEL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 198. ISRAEL MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 199. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 200. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 201. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 202. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 203. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 204. ITALY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 206. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 208. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 210. NETHERLANDS MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 211. NIGERIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 212. NIGERIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 213. NIGERIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 214. NIGERIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 215. NIGERIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 216. NIGERIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 217. NORWAY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 218. NORWAY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 219. NORWAY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 220. NORWAY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 221. NORWAY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. NORWAY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. POLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 224. POLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 225. POLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 226. POLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 227. POLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 228. POLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 229. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 230. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 231. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 232. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 233. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 234. QATAR MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 235. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 236. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 237. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 238. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 239. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 240. RUSSIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 242. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 244. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 246. SAUDI ARABIA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 250. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH AFRICA MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 253. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 254. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 255. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 256. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 257. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 258. SPAIN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 259. SWEDEN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 260. SWEDEN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 261. SWEDEN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 262. SWEDEN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 263. SWEDEN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 264. SWEDEN MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 266. SWITZERLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 268. SWITZERLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 269. SWITZERLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. SWITZERLAND MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. TURKEY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 272. TURKEY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 273. TURKEY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 274. TURKEY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 275. TURKEY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 276. TURKEY MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 281. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2018-2023 (USD MILLION)
  • TABLE 284. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY SOURCE, 2024-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
  • TABLE 286. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 288. UNITED KINGDOM MONOCLONAL ANTIBODY THERAPEUTICS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 289. MONOCLONAL ANTIBODY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 290. MONOCLONAL ANTIBODY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023